StockData
Evotec SE logo

Evotec SE (EVO) stock

EVONasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as EVOTF
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 8, 2026Score 4/30
$1.46−0.02 (-1.35%)

Close on Nov 18, 2026Market cap $519.11MP/E –Yield –

Evotec gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

For fiscal 2025 it was €114.22M, down 0.6% from the year before. The highest annual figure on record is €175.05M in fiscal 2023.

Annual gross profit

PeriodPeriod endValueChange
FY2025Dec 31, 2025€114.22M-0.6%
FY2024Dec 31, 2024€114.88M-34.4%
FY2023Dec 31, 2023€175.05M+0.6%
FY2022Dec 31, 2022€174.07M+14.9%
FY2021Dec 31, 2021€151.54M+20.5%
FY2020Dec 31, 2020€125.74M-5.4%
FY2019Dec 31, 2019€132.89M–

More Evotec figures

See a number that looks wrong?